中华皮肤科杂志 ›› 2012, Vol. 45 ›› Issue (4): 223-227.

• 论著 •    下一篇

系统性硬化病成纤维细胞单克隆Ⅲ型前胶原基因转录特性及丹参对其的调控研究

朱鹭冰1,高地1,李明2   

  1. 1. 复旦大学附属中山医院
    2. 上海市中山医院皮肤科
  • 收稿日期:2011-05-23 修回日期:2011-12-06 出版日期:2012-04-15 发布日期:2012-03-30
  • 通讯作者: 李明 E-mail:li.ming@zs-hospital.sh.cn
  • 基金资助:

    国家自然科学基金资助项目

Transcriptional characteristics of type Ⅲ procollagen gene in systemic scleroderma-derived fibroblast clones and their regulation by Radix Salviae miltiorrhizae

  • Received:2011-05-23 Revised:2011-12-06 Online:2012-04-15 Published:2012-03-30

摘要:

目的 探讨系统性硬化病(SS)患者皮损成纤维细胞单克隆Ⅲ型前胶原基因的转录特性及丹参对其的调控。方法 构建含有人Ⅲ型前胶原α1链(COL3A1)基因不同长度转录调控序列的重组质粒,利用瞬时转染、双荧光素酶报告基因技术检测其在SS患者皮损和正常人皮肤胶原合成异质性成纤维细胞克隆中的活性,并筛选出COL3A1近端转录调控靶序列。再通过转染、报告基因测活技术测定丹参注射液及其主要单体(丹参素钠、丹酚酸B、原儿茶醛和丹参酮ⅡA)对SS和正常人胶原合成异质性成纤维细胞克隆COL3A1近端启动区活性的调控。应用SPSS15.0软件进行统计学分析,基因转染、测活实验中,phCOLH30.1活性的比较采用t检验;丹参干预实验中,phCOLH30.1活性的比较采用双因素方差分析,若两因素存在交互作用,再进行单因素方差分析;若无交互作用,去除交互项,检验主效应。结果 6个COL3A1转录调控序列中,近端启动区-96 bp ~ +16 bp在SS组和正常对照组不同成纤维细胞克隆具有最高或较高的活性,且其活性与克隆的胶原合成能力呈正相关。丹参注射液下调COL3A1近端启动区在SS组(阴性对照组高、低胶原合成克隆COL3A1近端启动区相对活性分别为3.879 ± 0.309和2.150 ± 0.262,丹参注射液组分别为2.261 ± 0.619和1.462 ± 0.291,与阴性对照组相比,P均 < 0.01)和正常对照组高、低胶原合成克隆中的活性(阴性对照组分别为3.039 ± 0.271和2.223 ± 0.247,丹参注射液组分别为1.681 ± 0.263和1.121 ± 0.361,与阴性对照组相比,P均 < 0.01)。丹酚酸B下调COL3A1近端启动区在SS组高胶原合成克隆中的活性(为2.309 ± 0.524,与阴性对照组高胶原合成克隆相比,P < 0.01)和在正常对照组高、低胶原合成克隆中的活性(分别为2.126 ± 0.320和1.976 ± 0.362,与阴性对照组相比,P < 0.05)。丹参酮ⅡA仅下调COL3A1近端启动区在SS组高胶原合成克隆中的活性(2.975 ± 0.666,阴性对照组为5.379 ± 0.238,P < 0.01)。丹参素钠、原儿茶醛对COL3A1近端启动区在成纤维细胞克隆中的活性无抑制作用。结论 SS成纤维细胞高胶原合成克隆的Ⅲ型前胶原基因在转录水平即被激活并能被丹参注射液、单体丹酚酸B和丹参酮ⅡA抑制。

关键词: 丹参

Abstract:

Objective To study transcriptional characteristics of type Ⅲ procollagen gene in systemic scleroderma (SS)-derived fibroblast clones and their regulation by Radix Salviae miltiorrhizae(RSM). Methods Eight fibroblast clones with different collagen-producing capacity were previously obtained from patients with SS and normal human controls. Recombinant plasmids containing different deletions of the human alpha 1 chain of type 3 procollagen (COL3A1) gene promoter were constructed, and transiently transfected into the fibroblast clones. Dual-luciferase reporter assay system was used to evaluate the activities of these recombinants in the fibroblast clones and to select a proximal transcriptional regulatory sequence. Then, the fibroblast clones were transfected with the plasmid containing the selected regulatory sequence (phCOLH30.1) followed by the treatment with RSM injection (1 g/L) and active monomers of RSM, including salvianolic acid B (5 mg/L), tanshinone ⅡA(5 mg/L), danshensu (20 mg/L) and protocatechuic aldehyde (5 mg/L), for 48 hours. The transfected fibroblast clones receiving no drug treatment served as the water-soluble control, and those treated with only dimethyl sulfoxide as the lipid-soluble control. Subsequently, the fibroblasts were lysed and subjected to the quantification of cellular proteins and determination of luciferase activity. The activity of recombinant promoters was compared by t test for the selection of proximal transcriptional regulatory sequence, and the activity of phCOLH30.1 by two-way analysis of variance in the RSM-interfering test (if there was interaction, one-way analysis of variance was conducted; and if there was no interaction, the main effect was tested after the removal of interaction item). Results Of the 6 recombinants, the recombinant containing COL3A1 proximal promoter from -96 bp to +16 bp (phCOLH30.1) showed the highest transcriptional activity in nearly all of the fibroblast clones, and the activity was positively correlated with the collagen-producing capacity of fibroblast clones. Compared with the water-soluble control, RSM injection significantly downregulated the activity of phCOLH30.1 in fibroblast clones with high and low collagen-producing capacity from patients with SS (2.261 ± 0.619 vs. 3.879 ± 0.309, 1.462 ± 0.291 vs. 2.150 ± 0.262, both P < 0.01) and normal human controls (1.681 ± 0.263 vs. 3.039 ± 0.271, 1.121 ± 0.361 vs. 2.223 ± 0.247, both P < 0.01), salvianolic acid B decreased the phCOLH30.1 activity in SS-derived high collagen-producing fibroblast clones (2.309 ± 0.524, P < 0.01) and in the normal control fibroblast clones with high and low collagen-producing capacity (2.126 ± 0.320 and 1.976 ± 0.362, both P < 0.05). Tanshinone ⅡA only downregulated the phCOLH30.1 activity in SS-derived high collagen-producing fibroblast clones compared with the lipid-soluble control (2.975 ± 0.666 vs 5.379 ± 0.238, P < 0.01). Neither danshensu nor protocatechuic aldehyde showed inhibitory effects on phCOLH30.1 activity in SS-derived or normal control fibroblast clones. Conclusions The type Ⅲ procollagen gene is activated at the transcriptional level in high collagen-producing fibroblast clones from patients with SS, and the activation could be suppressed by RSM injection, salvianolic acid B and tanshinone ⅡA.

Key words: Salviae miltiorrhizae